Pharmaceuticals Janssen, Novavax plan Mexican late-stage COVID-19 vaccine trials

Janssen, Novavax plan Mexican late stage COVID-19 vaccine trials, minister says.

Phase 3 Johnson & Johnson’s Janssen (COVID-19) vaccine trial location announced in California.

MEXICO CITY (November 10, 2020) – Johnson & Johnson’s Janssen unit has received the green light to carry out late-stage trials for its coronavirus vaccine in Mexico, Foreign Minister Marcelo Ebrard on Tuesday, November 10th.

He said U.S. vaccine developer Novavax Inc earlier this month also presented health authorities with a request to conduct phase 3 testing in Mexico.

Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies)

The Janssen Pharmaceutical Company is a subsidiary of Johnson & Johnson. Janssen researches and produces medicines to treat various diseases, such as: heart diseases, HIV, Alzheimer’s disease, and different types of cancer. With over 30,000 employees, Janssen is headquartered in Beerse, Belgium.

Novavax Pharmaceutical is a company committed to delivering novel products that leverage innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases. They produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.

Source: El Economista

Mexico Daily Post